Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

16.89 -0.59 (-3.38%)
Official Closing Price Updated: 6:30 PM EDT, May 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
27 28 Next >
Eli Lilly's Migraine Drug Infringed Teva's Patents, Ordered To Pay $176M
A federal jury has asked Eli Lilly And Company (NYSE: LLY) to pay Teva Pharmaceuticals International GmbH $176.5 million after a trial to determine whether its migraine drug Emgality infringed three... 
Via Benzinga
Adding $100 to These 5 Stocks Would Be a Genius Move Right Now
You don't need a large pile of cash to begin building wealth on Wall Street. 
Via The Motley Fool
Teva to Present Latest Research from the CONNECT1 and CONNECT2 Clinical Trials at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Why Teva Stock Stumbled Again on Friday
A degree of uncertainty about the company's leadership compounded some rather discouraging recent developments. 
Via The Motley Fool
Why Teva Stock Sank On Thursday
There were two major developments with the company, both of which involved piles of money. 
Via The Motley Fool
Teva Highlights Long-Term Data From Chorea Associated-Huntington's Treatment
Via Benzinga
Teva To Start Nationwide Settlement Of Opioid Lawsuits From Next Year: Report
Via Benzinga
Teva's Migraine Treatment Effective In Patients With Co-Morbid Depression
Via Benzinga
Teva Pharmaceutical Industries (TEVA) Q3 2022 Earnings Call Transcript
TEVA earnings call for the period ending September 30, 2022. 
Via The Motley Fool
Teva Pharmaceutical Posts Lower Q3 Sales & Profits, Trims FY22 Revenue Outlook
Via Benzinga
Recap: Teva Pharmaceutical Q3 Earnings
Teva Pharmaceutical Indus (NYSE:TEVA) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Teva Reports Third Quarter 2022 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
Clinics Across Florida, New Jersey & California Advancing Mental Health in Underserved Communities – Awarded Funding from Teva Pharmaceuticals, Direct Relief and NAFC
From Teva Pharmaceutical Industries Limited
Via Business Wire
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion. 
Via Benzinga
Teva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO® (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s Disease
From Teva Pharmaceutical Industries Limited
Via Business Wire
Oil Output Cut May Tip Global Economy Into Recession, Elon Musk's Starship's First Space Tourist, Alphabet Approves Distribution Of Trump's Truth Social App: Top Stories Thursday, Oct. 13
Reuters 
Via Benzinga
FDA Signals Shortage For Teva Pharma's ADHD Drug Due To Manufacturing Delay
The FDA said that there was a shortage of Adderall after intermittent manufacturing delays at Teva Pharmaceutical Industries Ltd (NYSE: TEVA). 
Via Benzinga
Teva Under Suspicion On Practices To Stave Off Copaxone Competition
The European Commission, in an interim view, says Teva Pharmaceutical Industries Ltd (NYSE: TEVA) breached European Union (EU) antitrust rules over practices delaying competition to the multiple... 
Via Benzinga
Teva Reaches Agreement With Arkansas to Settle the State’s Price Fixing Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Largest-Ever Trial to Collect Information from Patients and Physicians About TD, its Impact and Progression Over Time, and Evaluate Treatment-Related Outcomes
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reaches Agreement With Georgia to Settle the State’s Price Fixing Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
European Drug Makers Say Higher Energy Costs Eating Margins: Report
Europe's drug makers have warned about stopping manufacturing some cheap generic medicines amid surging electricity costs. 
Via Benzinga
Teva Launches Honestly HD Website to Provide People Living With Huntington’s Disease (HD) Information, Inspiration and Resources on HD Chorea
From Teva Pharmaceutical Industries Limited
Via Business Wire
Biden Announces $1.5B To Combat US Overdose Epidemic, Support Recovery
Via Benzinga
Top Financial Media Stories Monday, September 19: Apple iPhone 14's Glitch With Some Third Party Apps, Tesla Wants To Double Sales In Germany, Ford Working On Smartphone Based Crash Detection Tech And More..
Reuters Volkswagen Eyes Juicy Valuations For Porsche IPO 
Via Benzinga
Studies Show Effectiveness of AJOVY®▼ (fremanezumab) for Treatment of Migraine in Patients With Co-morbid Depression
From Teva Pharmaceutical Industries Limited
Via Business Wire
CONNECT1 Study Published in Journal of Allergy and Clinical Immunology: In Practice Evaluates the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder and Digihaler System to Help Improve Asthma Management
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present First Data Set from the CONNECT1 Clinical Trial on ProAir® Digihaler® (albuterol sulfate) Inhalation Powder at the European Respiratory Society (ERS) International Congress 2022
From Teva Pharmaceutical Industries Limited
Via Business Wire
European Commission grants marketing authorization for Ranivisio▼®* (ranibizumab), a biosimilar to Lucentis®**, for age-related macular degeneration (AMD) the most common cause of blindness in developed countries
From Teva Pharmaceutical Industries Limited
Via Business Wire
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.